Assenagon Asset Management S.A. Decreases Stock Position in Establishment Labs Holdings Inc. $ESTA

Assenagon Asset Management S.A. lessened its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 55.7% in the first quarter, HoldingsChannel reports. The fund owned 51,305 shares of the company’s stock after selling 64,571 shares during the period. Assenagon Asset Management S.A.’s holdings in Establishment Labs were worth $2,913,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after acquiring an additional 9,557 shares during the last quarter. Geode Capital Management LLC lifted its position in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Establishment Labs during the second quarter valued at approximately $651,000. Nebula Research & Development LLC boosted its stake in shares of Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares during the period. Finally, Sei Investments Co. grew its holdings in shares of Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after purchasing an additional 5,668 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on ESTA shares. BTIG Research lifted their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Finally, Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 292,500 shares of company stock worth $20,591,021 in the last 90 days. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Price Performance

ESTA opened at $85.81 on Wednesday. The firm has a market cap of $2.53 billion, a PE ratio of -57.59 and a beta of 1.11. The stock has a 50-day moving average price of $74.45 and a 200-day moving average price of $70.56. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $90.50. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same period last year, the company posted ($0.70) earnings per share. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.